At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 137 enrolled
Drug / intervention
NXL104/ceftazidime +1 moredrug
Likely dose
NXL104/ceftazidime 125mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults
In Brief
A Phase 2 clinical trial evaluating NXL104/ceftazidime and Imipenem/Cilastatin for Complicated Urinary Tract Infection. Completed, enrolled 137 participants across 59 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsComplicated Urinary Tract Infection
CountriesJordan, Lebanon, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartNov 2008
Primary CompletionJun 2010
Study CompletionJul 2010
TodayJul 2026
First PostedJun 4, 2008
Enrollment StartNov 1, 2008
Primary CompletionJun 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.1 years ago
Interventions
NXL104/ceftazidimedrug
125mg/500mg TID
Imipenem/Cilastatindrug
4 x daily